Cost-Effectiveness of CAR T-Cell Therapy in Adults With Relapsed/Refractory Follicular Lymphoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Cost-Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Adults with Relapsed or Refractory Follicular Lymphoma
Blood Adv 2022 Nov 07;[EPub Ahead of Print], KC Potnis, M Di, I Isufi, L Gowda, SE Seropian, FM Foss, HP Forman, SF HuntingtonFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.